Cellectar Biosciences announced a partnership with FCS

Cellectar Biosciences announced a partnership with Florida Cancer Specialists & Research Institute, FCS, a world-class cancer care organization serving oncology patients throughout the state of Florida. Through this partnership, Cellectar and FCS will evaluate and further define unmet needs that exist across the Waldenstrom’s macroglobulinemia treatment landscape within the community oncology setting to advance patient care. “We are extremely pleased to be partnering with FCS, which shares our patient-centric vision and alignment on the unique benefits and significant potential of radiotherapeutics. This collaboration will help us to better understand patients’ and health care providers’ needs across the WM treatment landscape as we prepare for the potential launch of iopofosine I 131,” said James Caruso, president and CEO of Cellectar. “This partnership with FCS represents the first of several strategic collaborations we plan to establish with leading community based cancer care networks to facilitate and ensure patient access and clinical success with iopofosine.”